Aridis Pharmaceuticals Inc. [NASDAQ: ARDS] gained 14.85% or 0.3 points to close at $2.32 with a heavy trading volume of 3842864 shares. The company report on December 21, 2021 that Aridis Pharmaceuticals CEO Discusses Monoclonal Antibody Cocktail Protection Against COVID-19 Omicron Variant and Other Viruses in Fox Business Interview.
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that Vu Truong, Ph.D., Chief Executive Officer, was interviewed on Varney & Co., hosted by Stuart Varney, on Fox Business.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
It opened the trading session at $2.19, the shares rose to $2.44 and dropped to $2.08, the range by which the price of stock traded the whole day. The daily chart for ARDS points out that the company has recorded -67.87% loss over the past six months. However, it is still -22.75% lower than its most recent low trading price.
If we look at the average trading volume of 888.66K shares, ARDS reached to a volume of 3842864 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Aridis Pharmaceuticals Inc. [ARDS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARDS shares is $15.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARDS stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Aridis Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 19, 2020.
The Average True Range (ATR) for Aridis Pharmaceuticals Inc. is set at 0.39, with the Price to Sales ratio for ARDS stock in the period of the last 12 months amounting to 72.06.
Trading performance analysis for ARDS stock
Aridis Pharmaceuticals Inc. [ARDS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.55. With this latest performance, ARDS shares gained by 2.65% in over the last four-week period, additionally sinking by -67.87% over the last 6 months – not to mention a drop of -62.03% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARDS stock in for the last two-week period is set at 47.25, with the RSI for the last a single of trading hit 48.25, and the three-weeks RSI is set at 45.75 for Aridis Pharmaceuticals Inc. [ARDS]. The present Moving Average for the last 50 days of trading for this stock 2.68, while it was recorded at 2.34 for the last single week of trading, and 4.66 for the last 200 days.
Aridis Pharmaceuticals Inc. [ARDS]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Aridis Pharmaceuticals Inc. [ARDS] shares currently have an operating margin of -2240.10. Aridis Pharmaceuticals Inc.’s Net Margin is presently recorded at -2233.30.
Reflecting on the efficiency of the workforce at the company, Aridis Pharmaceuticals Inc. [ARDS] managed to generate an average of -$676,758 per employee. Receivables Turnover for the company is 0.86 with a Total Asset Turnover recorded at a value of 0.05.Aridis Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.80.
An analysis of insider ownership at Aridis Pharmaceuticals Inc. [ARDS]
There are presently around $4 million, or 18.20% of ARDS stock, in the hands of institutional investors. The top three institutional holders of ARDS stocks are: ARMISTICE CAPITAL, LLC with ownership of 1,068,444, which is approximately New of the company’s market cap and around 10.30% of the total institutional ownership; ROUMELL ASSET MANAGEMENT, LLC, holding 347,517 shares of the stock with an approximate value of $0.7 million in ARDS stocks shares; and VANGUARD GROUP INC, currently with $0.34 million in ARDS stock with ownership of nearly 5.996% of the company’s market capitalization.
Positions in Aridis Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 12 institutional holders increased their position in Aridis Pharmaceuticals Inc. [NASDAQ:ARDS] by around 1,332,181 shares. Additionally, 4 investors decreased positions by around 417,712 shares, while 4 investors held positions by with 241,397 shares. The mentioned changes placed institutional holdings at 1,991,290 shares, according to the latest SEC report filing. ARDS stock had 8 new institutional investments in for a total of 1,236,698 shares, while 3 institutional investors sold positions of 109,042 shares during the same period.